GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OSTO:MOB) » Definitions » Retained Earnings

Moberg Pharma AB (OSTO:MOB) Retained Earnings : kr-345.03 Mil (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Moberg Pharma AB Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Moberg Pharma AB's retained earnings for the quarter that ended in Mar. 2024 was kr-345.03 Mil.

Moberg Pharma AB's quarterly retained earnings declined from Sep. 2023 (kr-332.09 Mil) to Dec. 2023 (kr-338.53 Mil) and declined from Dec. 2023 (kr-338.53 Mil) to Mar. 2024 (kr-345.03 Mil).

Moberg Pharma AB's annual retained earnings declined from Dec. 2021 (kr-301.73 Mil) to Dec. 2022 (kr-317.44 Mil) and declined from Dec. 2022 (kr-317.44 Mil) to Dec. 2023 (kr-338.53 Mil).


Moberg Pharma AB Retained Earnings Historical Data

The historical data trend for Moberg Pharma AB's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB Retained Earnings Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.76 - -301.73 -317.44 -338.53

Moberg Pharma AB Quarterly Data
Mar19 Jun19 Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -322.92 -326.32 -332.09 -338.53 -345.03

Moberg Pharma AB Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Moberg Pharma AB  (OSTO:MOB) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Moberg Pharma AB (OSTO:MOB) Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Moberg Pharma has commercial agreements with partners in Europe and Canada, among others.